Sector
PharmaceuticalsOpen
₹868.55Prev. Close
₹868.55Turnover(Lac.)
₹0.02Day's High
₹868.55Day's Low
₹868.5552 Week's High
₹1,19052 Week's Low
₹736Book Value
₹446.41Face Value
₹10Mkt Cap (₹ Cr.)
104.23P/E
33.52EPS
25.91Divi. Yield
0.4Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
---|---|---|---|---|
Equity Capital | 1.2 | 1.2 | 1.2 | 1.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 52.37 | 49.64 | 44.43 | 39.11 |
Net Worth | 53.57 | 50.84 | 45.63 | 40.31 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 68.6 | 57.26 | 51.86 | 48.02 |
yoy growth (%) | 19.78 | 10.41 | 7.99 | 1.07 |
Raw materials | -31.16 | -25.64 | -23.83 | -20.22 |
As % of sales | 45.43 | 44.77 | 45.94 | 42.11 |
Employee costs | -9.79 | -9.3 | -7.33 | -6.9 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 7.9 | 4.32 | 2.45 | 4.89 |
Depreciation | -1.92 | -1.86 | -1.47 | -1.28 |
Tax paid | -2.57 | -1.1 | -0.44 | -2.19 |
Working capital | 2.51 | 0.57 | 1.74 | 3.08 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 19.78 | 10.41 | 7.99 | 1.07 |
Op profit growth | 55.54 | 40.92 | -34.9 | 3.8 |
EBIT growth | 66.14 | 53.04 | -41.88 | -4.64 |
Net profit growth | 65.34 | 60.34 | -25.51 | -31.08 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,705.55 | 95.71 | 4,09,218.58 | 753.53 | 0.94 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,600.65 | 79.35 | 1,75,226.52 | 667 | 0.45 | 2,536 | 561.08 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,741.9 | 63.7 | 1,26,637.21 | 551 | 0.16 | 2,567 | 224.34 |
Cipla Ltd CIPLA | 1,554.2 | 24.3 | 1,25,540.69 | 1,303.13 | 1.03 | 4,501.66 | 397.39 |
Dr Reddys Laboratories Ltd DRREDDY | 1,270.85 | 15.39 | 1,06,062.83 | 2,961.2 | 0.63 | 7,788.7 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Rajendra R Shah
Non-Executive & Non-Independent Director
Dilip R Shah
Non-Executive & Non-Independent Director
Paresh Mistry
Non-Executive & Non-Independent Director
Janki Shah
Independent Director
Jayantilal D Raval
Chairman & Independent Director
SANJAY SHANTILAL PATEL
Company Sec. & Compli. Officer
Krishna Shah
1st Floor 18 Shreeji Bhuwan 51,
Princess Street Mangaladas Rd,
Maharashtra - 400002
Tel: 91-22-66372841
Website: http://www.mercurylabs.com
Email: secretarial@mercurylabs.com, mllbrd@mercurylabs.co
B-102&103 Shangrila,
Complex First Floor, Akota,
Vadodara - 390 020
Tel: 91-265-2356573/23567
Website: www.linkintime.co.in
Email: vadodara@linktime.co.in
Summary
Mercury Laboratories Limited, the registered partnership firm started its business activity in year 1962. Subsequently, the Company converted into Private Limited Company & incorporated in February, 1...
Read More
Reports by Mercury Laboratories Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.